vs
COLONY BANKCORP INC（CBAN）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
COLONY BANKCORP INC的季度营收约是REGENXBIO Inc.的1.3倍（$39.9M vs $30.3M），COLONY BANKCORP INC净利率更高（20.6% vs -221.3%，领先241.9%），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 19.6%）
Colony Bankcorp Inc是总部位于美国的银行控股公司，旗下运营Colony Bank，主要面向佐治亚州的个人消费者与中小企业，提供储蓄账户、贷款、抵押及财富管理等全方位个人及商业金融服务。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
CBAN vs RGNX — 直观对比
营收规模更大
CBAN
是对方的1.3倍
$30.3M
净利率更高
CBAN
高出241.9%
-221.3%
两年增速更快
RGNX
近两年复合增速
19.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $39.9M | $30.3M |
| 净利润 | $8.2M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | — | -190.0% |
| 净利率 | 20.6% | -221.3% |
| 营收同比 | — | 43.0% |
| 净利润同比 | 24.1% | -31.2% |
| 每股收益（稀释后） | — | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CBANRGNX
| Q1 26 | $39.9M | — | ||
| Q4 25 | $36.9M | $30.3M | ||
| Q3 25 | $32.8M | $29.7M | ||
| Q2 25 | $32.5M | $21.4M | ||
| Q1 25 | $30.0M | $89.0M | ||
| Q4 24 | $30.8M | $21.2M | ||
| Q3 24 | $28.6M | $24.2M | ||
| Q2 24 | $27.9M | $22.3M |
净利润CBANRGNX
| Q1 26 | $8.2M | — | ||
| Q4 25 | — | $-67.1M | ||
| Q3 25 | $5.8M | $-61.9M | ||
| Q2 25 | $8.0M | $-70.9M | ||
| Q1 25 | $6.6M | $6.1M | ||
| Q4 24 | — | $-51.2M | ||
| Q3 24 | $5.6M | $-59.6M | ||
| Q2 24 | $5.5M | $-53.0M |
毛利率CBANRGNX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% |
营业利润率CBANRGNX
| Q1 26 | — | — | ||
| Q4 25 | 25.9% | -190.0% | ||
| Q3 25 | 22.2% | -176.3% | ||
| Q2 25 | 30.9% | -296.3% | ||
| Q1 25 | 27.6% | 13.6% | ||
| Q4 24 | 28.8% | -242.1% | ||
| Q3 24 | 24.6% | -256.6% | ||
| Q2 24 | 24.8% | -251.3% |
净利率CBANRGNX
| Q1 26 | 20.6% | — | ||
| Q4 25 | — | -221.3% | ||
| Q3 25 | 17.7% | -208.3% | ||
| Q2 25 | 24.6% | -331.8% | ||
| Q1 25 | 22.0% | 6.8% | ||
| Q4 24 | — | -241.3% | ||
| Q3 24 | 19.7% | -246.3% | ||
| Q2 24 | 19.6% | -237.7% |
每股收益（稀释后）CBANRGNX
| Q1 26 | — | — | ||
| Q4 25 | $0.42 | $-1.30 | ||
| Q3 25 | $0.33 | $-1.20 | ||
| Q2 25 | $0.46 | $-1.38 | ||
| Q1 25 | $0.38 | $0.12 | ||
| Q4 24 | $0.43 | $-0.99 | ||
| Q3 24 | $0.32 | $-1.17 | ||
| Q2 24 | $0.31 | $-1.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $295.8M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $380.4M | $102.7M |
| 总资产 | $3.7B | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CBANRGNX
| Q1 26 | $295.8M | — | ||
| Q4 25 | — | $230.1M | ||
| Q3 25 | — | $274.2M | ||
| Q2 25 | — | $323.3M | ||
| Q1 25 | — | $267.9M | ||
| Q4 24 | — | $234.7M | ||
| Q3 24 | — | $255.5M | ||
| Q2 24 | — | $290.4M |
总债务CBANRGNX
| Q1 26 | — | — | ||
| Q4 25 | $258.1M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $248.0M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益CBANRGNX
| Q1 26 | $380.4M | — | ||
| Q4 25 | $375.9M | $102.7M | ||
| Q3 25 | $302.3M | $161.5M | ||
| Q2 25 | $293.9M | $213.7M | ||
| Q1 25 | $286.9M | $274.2M | ||
| Q4 24 | $278.7M | $259.7M | ||
| Q3 24 | $276.1M | $301.4M | ||
| Q2 24 | $264.7M | $348.3M |
总资产CBANRGNX
| Q1 26 | $3.7B | — | ||
| Q4 25 | $3.7B | $453.0M | ||
| Q3 25 | $3.2B | $525.2M | ||
| Q2 25 | $3.1B | $581.0M | ||
| Q1 25 | $3.2B | $490.9M | ||
| Q4 24 | $3.1B | $466.0M | ||
| Q3 24 | $3.1B | $519.1M | ||
| Q2 24 | $3.0B | $569.4M |
负债/权益比CBANRGNX
| Q1 26 | — | — | ||
| Q4 25 | 0.69× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.89× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-52.8M |
| 自由现金流率自由现金流/营收 | — | -174.0% |
| 资本支出强度资本支出/营收 | — | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流CBANRGNX
| Q1 26 | — | — | ||
| Q4 25 | $-5.5M | $-52.3M | ||
| Q3 25 | $14.4M | $-56.0M | ||
| Q2 25 | $15.8M | $-49.3M | ||
| Q1 25 | $17.9M | $33.6M | ||
| Q4 24 | $23.4M | $-31.6M | ||
| Q3 24 | $20.5M | $-40.5M | ||
| Q2 24 | $1.1M | $-45.5M |
自由现金流CBANRGNX
| Q1 26 | — | — | ||
| Q4 25 | $-6.9M | $-52.8M | ||
| Q3 25 | $14.1M | $-56.5M | ||
| Q2 25 | $15.8M | $-49.7M | ||
| Q1 25 | $17.6M | $32.6M | ||
| Q4 24 | $22.3M | $-32.7M | ||
| Q3 24 | $20.2M | $-40.9M | ||
| Q2 24 | $990.0K | $-46.0M |
自由现金流率CBANRGNX
| Q1 26 | — | — | ||
| Q4 25 | -18.7% | -174.0% | ||
| Q3 25 | 42.9% | -189.9% | ||
| Q2 25 | 48.5% | -232.8% | ||
| Q1 25 | 58.7% | 36.6% | ||
| Q4 24 | 72.5% | -154.2% | ||
| Q3 24 | 70.6% | -168.9% | ||
| Q2 24 | 3.5% | -206.2% |
资本支出强度CBANRGNX
| Q1 26 | — | — | ||
| Q4 25 | 3.7% | 1.7% | ||
| Q3 25 | 1.1% | 1.7% | ||
| Q2 25 | 0.3% | 1.8% | ||
| Q1 25 | 1.2% | 1.2% | ||
| Q4 24 | 3.5% | 5.1% | ||
| Q3 24 | 1.0% | 1.3% | ||
| Q2 24 | 0.5% | 2.1% |
现金转化率CBANRGNX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 2.48× | — | ||
| Q2 25 | 1.99× | — | ||
| Q1 25 | 2.71× | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.64× | — | ||
| Q2 24 | 0.20× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CBAN
| Net Interest Income | $29.2M | 73% |
| Noninterest Income | $10.7M | 27% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
